C07K 16/2893
Against cd52
Official title: {against CD52}
C07K16/2893 (Against cd52) appears on 173 US grants and 342 published applications in this corpus.
Search patents in C07K- Granted patents
- 173
- Published applications
- 342
- Assignees
- 85
- Inventors
- 328
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 4 | 0 |
| 1997 | 3 | 0 |
| 1998 | 3 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 2 |
| 2003 | 1 | 2 |
| 2004 | 0 | 7 |
| 2005 | 0 | 7 |
| 2006 | 0 | 9 |
| 2007 | 3 | 20 |
| 2008 | 2 | 12 |
| 2009 | 2 | 15 |
| 2010 | 3 | 12 |
| 2011 | 4 | 8 |
| 2012 | 9 | 11 |
| 2013 | 7 | 13 |
| 2014 | 15 | 16 |
| 2015 | 6 | 20 |
| 2016 | 5 | 23 |
| 2017 | 16 | 29 |
| 2018 | 7 | 10 |
| 2019 | 24 | 14 |
| 2020 | 9 | 18 |
| 2021 | 10 | 20 |
| 2022 | 2 | 20 |
| 2023 | 7 | 15 |
| 2024 | 14 | 14 |
| 2025 | 9 | 11 |
| 2026 | 5 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Site-specific glycoengineering of targeting moieties7 Jul 2026US 12,674,003 B2Genzyme Corporation
- Antibody variant combinations and uses thereof30 Jun 2026US 12,668,641 B2Genmab B.V.
- Polypeptide variants and uses thereof9 Jun 2026US 12,649,798 B2Genmab B.V.
- Anti-αβTCR antibody28 Apr 2026US 12,612,458 B2Genzyme Corporation
- Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells24 Mar 2026US 12,583,905 B2Allogene Therapeutics, Inc.
- Fc containing polypeptides with altered glycosylation and reduced effector function17 Sep 2026US 2026/0274926 A1Genzyme Corporation
- Methods for enhancing tcrab+ cell depletion efficiency17 Sep 2026US 2026/0274949 A1Allogene Therapeutics, Inc.
- Use of quinolinone derivative in treatment of immune thrombocytopenia11 Jun 2026US 2026/0158028 A1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Immunotherapeutic Proteins Comprising an Fc Region Component With a Mutation at Position 42911 Jun 2026US 2026/0158160 A1Macfarlane Burnet Institute for Medical Research and Public Health Limited
- Methods and compositions for inhibiting cd32b expressing cells11 Jun 2026US 2026/0159590 A1Xencor, Inc.
Most cited
By later US patents
- Optimized Fc variants463US 7,317,091 B2Xencor, Inc. · 2008
- Optimized Fc variants and methods for their generation218US 7,662,925 B2Xencor, Inc. · 2010
- Fc variants with altered binding to FcRn193US 8,367,805 B2Xencor, Inc. · 2013
- Method for culturing Chinese hamster ovary cells186US 5,633,162 AGlaxo Wellcome Inc. · 1997
- Optimized FC variants176US 8,188,231 B2Xencor, Inc. · 2012